Shallow whole genome re-sequencing to precisely predict benefit from PARP inhibitor

Oncogene. 2023 Nov;42(48):3543-3544. doi: 10.1038/s41388-023-02871-8. Epub 2023 Nov 9.

Authors

José L Sandoval¹, S Intidhar Labidi-Galy^{2

3}

Affiliations

¹ Department of Oncology, Hopitaux Universitaires de Geneve, Geneva, Switzerland.
² Department of Oncology, Hopitaux Universitaires de Geneve, Geneva, Switzerland. intidhar.labidi-galy@hcuge.ch.
³ Department of Medicine, Center of Translational Research in Onco-Hematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland. intidhar.labidi-galy@hcuge.ch.

PMID: 37945747
DOI: 10.1038/s41388-023-02871-8

No abstract available

Publication types

Editorial

MeSH terms

Antineoplastic Agents*
Humans
Poly(ADP-ribose) Polymerase Inhibitors* / pharmacology
Poly(ADP-ribose) Polymerase Inhibitors* / therapeutic use
Whole Genome Sequencing

Substances

Poly(ADP-ribose) Polymerase Inhibitors
Antineoplastic Agents